Which has better earnings and valuation, AKTX or MREO?

Akari Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Mereo BioPharma Group $500K 98.77 -$41.88M -$0.05 N/A

Is AKTX or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Mereo BioPharma Group N/A -81.28% -70.45%

Does the media prefer AKTX or MREO?

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Mereo BioPharma Group's average media sentiment score of 1.43 beat Akari Therapeutics' score of 0.59 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ATYR or AKTX?

Akari Therapeutics has lower revenue, but higher earnings than aTyr Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 254.93 -$74.12M -$0.73 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is ATYR or AKTX more profitable?

aTyr Pharma's return on equity of -100.14% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Akari Therapeutics N/A -123.29% -63.01%

Does the media refer more to ATYR or AKTX?

In the previous week, aTyr Pharma and aTyr Pharma both had 3 articles in the media. aTyr Pharma's average media sentiment score of 0.96 beat Akari Therapeutics' score of 0.59 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AKTX or DWTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is AKTX or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Dogwood Therapeutics N/A -108.57% -30.28%

Which has higher earnings & valuation, AKTX or MGX?

Akari Therapeutics has higher earnings, but lower revenue than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Metagenomi $25.21M 1.81 -$87.87M -$2.30 N/A

Does the media refer more to AKTX or MGX?

In the previous week, Akari Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.94 beat Akari Therapeutics' score of 0.59 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DYAI or AKTX?

Dyadic International has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyadic International $3.09M 12.50 -$7.36M -$0.23 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Does the media prefer DYAI or AKTX?

In the previous week, Dyadic International had 3 more articles in the media than Akari Therapeutics. MarketBeat recorded 6 mentions for Dyadic International and 3 mentions for Akari Therapeutics. Dyadic International's average media sentiment score of 0.61 beat Akari Therapeutics' score of 0.59 indicating that Dyadic International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akari Therapeutics (AKTX) Competitors

$8.43 -0.03 (-0.35%)

Closing price 07/28/2026 04:00 PM Eastern

Extended Trading

$8.51 +0.08 (+0.95%)

As of 07/28/2026 04:10 PM Eastern

Compare

AKTX vs. MREO, ATYR, DWTX, MGX, and DYAI

Should you buy Akari Therapeutics stock or one of its competitors? MarketBeat compares Akari Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akari Therapeutics include Mereo BioPharma Group (MREO), aTyr Pharma (ATYR), Dogwood Therapeutics (DWTX), Metagenomi (MGX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry.

How does Akari Therapeutics compare to Mereo BioPharma Group?

Akari Therapeutics (NASDAQ:AKTX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Mereo BioPharma Group's average media sentiment score of 1.43 beat Akari Therapeutics' score of 0.59 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akari Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Mereo BioPharma Group	$500K	98.77	-$41.88M	-$0.05	N/A

Akari Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mereo BioPharma Group's return on equity of -81.28% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 283.55%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 950.42%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Akari Therapeutics and Mereo BioPharma Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Akari Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Akari Therapeutics has lower revenue, but higher earnings than aTyr Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	254.93	-$74.12M	-$0.73	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

In the previous week, aTyr Pharma and aTyr Pharma both had 3 articles in the media. aTyr Pharma's average media sentiment score of 0.96 beat Akari Therapeutics' score of 0.59 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

aTyr Pharma's return on equity of -100.14% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Akari Therapeutics	N/A	-123.29%	-63.01%

aTyr Pharma presently has a consensus target price of $17.00, indicating a potential upside of 3,341.30%. Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 283.55%. Given aTyr Pharma's higher possible upside, equities research analysts clearly believe aTyr Pharma is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

aTyr Pharma has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Summary

aTyr Pharma and Akari Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Dogwood Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dogwood Therapeutics' return on equity of -108.57% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

In the previous week, Akari Therapeutics had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Akari Therapeutics' score of 0.59 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Positive
Dogwood Therapeutics	Positive

Akari Therapeutics presently has a consensus price target of $32.33, indicating a potential upside of 283.55%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 674.19%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Akari Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Summary

Dogwood Therapeutics beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Metagenomi?

Akari Therapeutics (NASDAQ:AKTX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

In the previous week, Akari Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.94 beat Akari Therapeutics' score of 0.59 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akari Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Akari Therapeutics currently has a consensus price target of $32.33, suggesting a potential upside of 283.55%. Metagenomi has a consensus price target of $7.00, suggesting a potential upside of 478.51%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Akari Therapeutics has higher earnings, but lower revenue than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Metagenomi	$25.21M	1.81	-$87.87M	-$2.30	N/A

5.1% of Akari Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Akari Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Metagenomi	-384.61%	-51.23%	-36.62%

Summary

Metagenomi beats Akari Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Akari Therapeutics compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Dyadic International has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	12.50	-$7.36M	-$0.23	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Dyadic International currently has a consensus target price of $3.00, indicating a potential upside of 183.02%. Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 283.55%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dyadic International has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

In the previous week, Dyadic International had 3 more articles in the media than Akari Therapeutics. MarketBeat recorded 6 mentions for Dyadic International and 3 mentions for Akari Therapeutics. Dyadic International's average media sentiment score of 0.61 beat Akari Therapeutics' score of 0.59 indicating that Dyadic International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Akari Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Akari Therapeutics' return on equity of -123.29% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Akari Therapeutics	N/A	-123.29%	-63.01%

Summary

Akari Therapeutics beats Dyadic International on 8 of the 13 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTX vs. The Competition

Export

Metric	Akari Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.68M	$3.68B	$7.08B	$12.19B
Dividend Yield	N/A	2.17%	2.66%	8.55%
P/E Ratio	N/A	21.89	27.24	23.75
Price / Sales	N/A	295.81	520.20	87.89
Price / Cash	N/A	153.52	49.60	59.05
Price / Book	0.34	7.94	10.24	6.06
Net Income	-$17.30M	$23.81M	$3.60B	$336.44M
7 Day Performance	-14.07%	-2.65%	-0.96%	-1.50%
1 Month Performance	-13.00%	-6.69%	-3.60%	-4.62%
1 Year Performance	-80.48%	36.08%	20.54%	15.02%

Akari Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	3.4825 of 5 stars	$8.43 -0.4%	$32.33 +283.6%	-81.4%	$9.68M	N/A	N/A	9	Gap Up
MREO Mereo BioPharma Group	3.3869 of 5 stars	$0.31 +0.2%	$3.25 +962.8%	-82.4%	$48.72M	$500K	N/A	40	Positive News Short Interest Decrease
ATYR aTyr Pharma	3.5463 of 5 stars	$0.49 -0.1%	$17.00 +3,398.7%	-92.0%	$47.69M	$190K	N/A	53	Short Interest Decrease
DWTX Dogwood Therapeutics	3.0874 of 5 stars	$1.40 +1.4%	$12.00 +757.1%	-67.5%	$46.41M	N/A	N/A	5
MGX Metagenomi	3.8386 of 5 stars	$1.22 flat	$7.00 +473.8%	-52.0%	$45.93M	$25.21M	N/A	236	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akari Therapeutics (AKTX) Competitors

AKTX vs. MREO, ATYR, DWTX, MGX, and DYAI

How does Akari Therapeutics compare to Mereo BioPharma Group?

Summary

How does Akari Therapeutics compare to aTyr Pharma?

Summary

How does Akari Therapeutics compare to Dogwood Therapeutics?

Summary

How does Akari Therapeutics compare to Metagenomi?

Summary

How does Akari Therapeutics compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akari Therapeutics (AKTX) Competitors

AKTX vs. MREO, ATYR, DWTX, MGX, and DYAI

How does Akari Therapeutics compare to Mereo BioPharma Group?

Does the media prefer AKTX or MREO?

Which has better earnings and valuation, AKTX or MREO?

Which has more volatility and risk, AKTX or MREO?

Do institutionals and insiders hold more shares of AKTX or MREO?

Is AKTX or MREO more profitable?

Do analysts recommend AKTX or MREO?

Summary

How does Akari Therapeutics compare to aTyr Pharma?

Which has higher valuation & earnings, ATYR or AKTX?

Does the media refer more to ATYR or AKTX?

Do institutionals and insiders have more ownership in ATYR or AKTX?

Is ATYR or AKTX more profitable?

Do analysts prefer ATYR or AKTX?

Which has more volatility & risk, ATYR or AKTX?

Summary

How does Akari Therapeutics compare to Dogwood Therapeutics?

Do insiders and institutionals believe in AKTX or DWTX?

Is AKTX or DWTX more profitable?

Which has better valuation & earnings, AKTX or DWTX?

Does the media prefer AKTX or DWTX?

Do analysts prefer AKTX or DWTX?

Which has more volatility and risk, AKTX or DWTX?

Summary

How does Akari Therapeutics compare to Metagenomi?

Does the media refer more to AKTX or MGX?

Which has more volatility & risk, AKTX or MGX?

Do analysts rate AKTX or MGX?

Which has higher earnings & valuation, AKTX or MGX?

Do insiders and institutionals hold more shares of AKTX or MGX?

Is AKTX or MGX more profitable?

Summary

How does Akari Therapeutics compare to Dyadic International?

Which has higher valuation & earnings, DYAI or AKTX?

Do analysts rate DYAI or AKTX?

Which has more volatility and risk, DYAI or AKTX?

Does the media prefer DYAI or AKTX?

Do insiders & institutionals have more ownership in DYAI or AKTX?

Is DYAI or AKTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools